Qingdao Central Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction

First Posted Date
2021-09-20
Last Posted Date
2023-09-21
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
300
Registration Number
NCT05050500
Locations
🇨🇳

Mengmei Li, Qingdao, Shandong, China

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Phase 2
Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Osimertinib Oral Tablet
First Posted Date
2021-07-23
Last Posted Date
2023-03-29
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
20
Registration Number
NCT04974879
Locations
🇨🇳

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Phase 2
Recruiting
Conditions
Carcinoma, Adenoid Cystic
Interventions
Drug: EGFR-TK Inhibitor
First Posted Date
2021-07-23
Last Posted Date
2023-03-29
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
20
Registration Number
NCT04974866
Locations
🇨🇳

Qingdao central Hospital, Qingdao, Shandong, China

Maintenance Therapy for Small-cell Lung Cancer

Phase 2
Completed
Conditions
Progression Free Survival
Interventions
Drug: cis Platinum, etoposide, S1
First Posted Date
2018-12-10
Last Posted Date
2023-03-29
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
90
Registration Number
NCT03769935
Locations
🇨🇳

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

Phase 2
Completed
Conditions
Overall Survival
Interventions
Drug: Irinotecan,Oxaliplatin, and S1
First Posted Date
2018-10-31
Last Posted Date
2023-03-29
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
47
Registration Number
NCT03726021
Locations
🇨🇳

Qingdao Central Hospital, Qingdao, China

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

First Posted Date
2018-06-21
Last Posted Date
2018-07-02
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
20
Registration Number
NCT03564977
Locations
🇨🇳

Qingdao Central Hospital, Qingdao, Shandong, China

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

First Posted Date
2016-11-09
Last Posted Date
2018-02-14
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
147
Registration Number
NCT02959749
Locations
🇨🇳

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Completed
Conditions
EGFR-TKI Resistant Mutation
Interventions
Other: history data
First Posted Date
2015-10-14
Last Posted Date
2018-02-14
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
30
Registration Number
NCT02575560
Locations
🇨🇳

Qingdao Central Hospital, Qingdao, Shandong, China

Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

First Posted Date
2013-09-04
Last Posted Date
2023-03-29
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
5
Registration Number
NCT01934478
Locations
🇨🇳

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Liver Cancer
Interventions
Drug: Sorafenib
Other: Best Supportive Care
First Posted Date
2013-08-30
Last Posted Date
2018-02-14
Lead Sponsor
Qingdao Central Hospital
Target Recruit Count
86
Registration Number
NCT01932385
Locations
🇨🇳

Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy